Harvard Enterprise Value Over E B I T D A from 2010 to 2024

HBIO Stock  USD 2.20  0.01  0.46%   
Harvard Bioscience Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to grow to 34.70 this year. During the period from 2010 to 2024, Harvard Bioscience Enterprise Value Over EBITDA quarterly data regression pattern had range of 1.3 K and standard deviation of  311.69. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
33.0433213
Current Value
34.7
Quarterly Volatility
311.69010182
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Harvard Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harvard Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 M, Interest Expense of 3.8 M or Total Revenue of 96.8 M, as well as many indicators such as Price To Sales Ratio of 1.72, Dividend Yield of 0.0022 or PTB Ratio of 4.65. Harvard financial statements analysis is a perfect complement when working with Harvard Bioscience Valuation or Volatility modules.
  
Check out the analysis of Harvard Bioscience Correlation against competitors.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.

Latest Harvard Bioscience's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Harvard Bioscience over the last few years. It is Harvard Bioscience's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harvard Bioscience's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Very volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Harvard Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(39.74)
Coefficient Of Variation(784.34)
Mean Deviation149.02
Median28.73
Standard Deviation311.69
Sample Variance97,151
Range1.3K
R-Value0.05
Mean Square Error104,337
R-Squared0
Significance0.85
Slope3.65
Total Sum of Squares1.4M

Harvard Enterprise Value Over E B I T D A History

2024 34.7
2023 33.04
2022 166.35
2021 28.73
2020 37.42
2019 21.44
2018 31.05

About Harvard Bioscience Financial Statements

Harvard Bioscience investors utilize fundamental indicators, such as Enterprise Value Over E B I T D A, to predict how Harvard Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 33.04  34.70 
When determining whether Harvard Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Harvard Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Harvard Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Harvard Bioscience Stock:
Check out the analysis of Harvard Bioscience Correlation against competitors.
To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.80)
Earnings Share
(0.33)
Revenue Per Share
2.258
Quarterly Revenue Growth
(0.13)
Return On Assets
(0.02)
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.